The symptoms evolution of long COVID‑19 (SE-LC19): a new patient-reported content valid instrument.

Autor: Rofail D; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA. diana.rofail@regeneron.com., Somersan-Karakaya S; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA., Mylonakis E; Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, RI, USA.; Department of Medicine, Houston Methodist Hospital, Houston, TX, USA., Choi JY; Modus Outcomes, Cambridge, MA, USA., Przydzial K; Modus Outcomes, Cambridge, MA, USA., Marquis S; Modus Outcomes, Cambridge, MA, USA., Zhao Y; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA., Hussein M; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA., Norton TD; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA., Podolanczuk AJ; Weill Cornell Medical College, New York, NY, USA., Geba GP; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA.

Publikováno v: Journal of patient-reported outcomes [J Patient Rep Outcomes] 2024 Aug 09; Vol. 8 (1), pp. 87. Date of Electronic Publication: 2024 Aug 09.

Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles.

Autor: Li D; Global Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA., Xu M; Global Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA., Hooper AT; Global Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA., Rofail D; Global Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA., Mohammadi KA; Global Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA., Chen Y; Global Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA., Ali S; Global Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA., Norton T; Global Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA., Weinreich DM; Global Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA., Musser BJ; Global Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA., Hamilton JD; Global Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA., Geba GP; Global Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY, 10591, USA. gregory.geba@regeneron.com.

Publikováno v: Scientific reports [Sci Rep] 2023 Aug 07; Vol. 13 (1), pp. 12784. Date of Electronic Publication: 2023 Aug 07.

Development and Preliminary Validation of an Instrument to Measure Symptoms and Impacts in Patients with Proliferative Diabetic Retinopathy.

Autor: Rofail D; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA. diana.rofail@regeneron.com., Sherman S; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA., Hartford C; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA., Levine A; Modus Outcomes, a Division of THREAD, Cambridge, MA, USA.; Center for the Evaluation of Value and Risk in Health, Boston, MA, USA., Baldasaro J; Modus Outcomes, a Division of THREAD, Cambridge, MA, USA., Marquis P; Modus Outcomes, a Division of THREAD, Cambridge, MA, USA., Rao R; Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA., Do DV; Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.

Publikováno v: Advances in therapy [Adv Ther] 2023 Apr; Vol. 40 (4), pp. 1773-1786. Date of Electronic Publication: 2023 Feb 27.

Experience of Daily Life with Generalized Myasthenia Gravis: A Qualitative Investigation and Assessment of Instrument Content Validity.

Autor: Hartford CA; Regeneron Pharmaceuticals, Inc., 1 Rockwood Rd, Sleepy Hollow, NY, 10591, USA. christopher.hartford@regeneron.com., Sherman SA; Regeneron Pharmaceuticals, Inc., 1 Rockwood Rd, Sleepy Hollow, NY, 10591, USA., Karantzoulis S; IQVIA, Durham, NC, USA., Guillemin I; IQVIA, Lyon, France., Phinney MG; IQVIA, Durham, NC, USA., Kelly KL; IQVIA, Durham, NC, USA., Negron KE; IQVIA, Durham, NC, USA., Raja SM; Duke University Medical Center, Durham, NC, USA., Rofail D; Regeneron Pharmaceuticals, Inc., 1 Rockwood Rd, Sleepy Hollow, NY, 10591, USA.

Publikováno v: Neurology and therapy [Neurol Ther] 2023 Dec; Vol. 12 (6), pp. 2079-2099. Date of Electronic Publication: 2023 Sep 25.

A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence

Autor: Dias Barbosa C, Balp M-M, Kulich K, Germain N, Rofail D

Publikováno v: Patient Preference and Adherence, Vol 2012, Iss default, Pp 39-48 (2012)

Carla Dias Barbosa1, Maria-Magdalena Balp2, Károly Kulich2, Nicola Germain1, Diana Rofail31Mapi Consultancy, Lyon, France; 2Novartis Pharma AG, Basel, Switzerland; 3Mapi Values, Macclesfield, Cheshire, United KingdomPurpose: To explore the published

Externí odkaz: https://doaj.org/article/41271da5f46d4511922d82f3128b0665